Bertis participates in Children’s Traffic Safety Relay Challenge

- Joined in a relay campaign launched by the Ministry of the Interior and Safety and encouraged the spread of a mature traffic culture

for children’s safety

- Han Won-sik, chief director of “DCGEN,” a company which specializes in clinical genome analysis, was tapped for the next relay

On October 6, Bertis Inc. (co-CEOs Dong-young Noh and Seung-man Han), a company that has developed a proteomics-based early diagnosis technology, announced that they had participated in the “Children’s Traffic Safety Relay Challenge” to improve awareness of children’s traffic safety.

The Children’s Traffic Safety Relay Challenge is a campaign launched by the Ministry of the Interior and Safety to raise awareness of traffic accidents that occur in child protection zones and establish a culture that puts the protection of children first. Since the last December, political and business leaders as well as citizens have participated in the campaign, supporting the creation of a safe traffic environment.

On October 6, at the Bertis Seoul office, CEO Seung-man Han took part in the relay campaign, holding a picket which said, “(1) Stop (2) Look Right and Left (3) for Three Seconds (4) to Prevent Accidents!” stressing the importance of practicing proper traffic safety to employees. CEO Seung-man Han participated in the campaign after being designated by Medical IP CEO Sang-joon Park. He, in turn, selected Won-sik Han, chief director of DCGEN, a company specializing in clinical genome analysis, as his successor.

“I think diseases can be prevented through technology, and accidents can be avoided through the creation of a safety culture. I expect a mature traffic culture will be formed through this challenge so that children can grow up in a safer environment,” CEO Seung-man Han said.

Bertis has developed “MASTOCHECK,” a blood test that enables the diagnosis of breast cancer in the early stages through major medical centers. The company is currently developing diagnostic technologies for cardiovascular disease, pancreatic cancer, and ovarian cancer based on its unrivaled quantitative proteomics technology.